- 17Volume 4, 2021Apr 06, Issue 7Mar 23, Issue 6Mar 09, Issue 5Feb 23, Issue 4Feb 09, Issue 3Jan 26, Issue 01
- 16Volume 3, 2020Dec 15, Issue 25Dec 01, Issue 24Nov 17, Issue 23Oct 06, Issue 20Sep 08, Issue 18Aug 25, Issue 17Jul 14, Issue 14Jun 30, Issue 13Jun 16, Issue 12Jun 02, Issue 11May 19, Issue 10May 05, Issue 9Mar 10, Issue 5Feb 25, Issue 4Feb 04, Issue 3Jan 21, Issue 2Jan 07, Issue 01
- 15Volume 2, 2019Dec 17, Issue 22Nov 12, Issue 20Oct 28, Issue 19Oct 15, Issue 18Sep 03, Issue 15Aug 21, Issue 14Aug 05, Issue 13Jul 22, Issue 12Jul 08, Issue 11Jun 03, Issue 9May 13, Issue 8Apr 22, Issue 7Mar 11, Issue 4Feb 04, Issue 2Jan 21, Issue 1
- 14Volume 1, 2018Dec 21, Issue 12Dec 03, Issue 11Nov 19, Issue 10Nov 05, Issue 9Oct 22, Issue 8Oct 09, Issue 7Sep 24, Issue 6Sep 10, Issue 5Aug 15, Issue 4Jul 15, Issue 3Jul 01, Issue 1
Agenus on Twitter
Agenus expects this therapy to be effective in both liquid and solid tumors based on preclinical models and to be potentially more affordable and more accessible than currently approved cell therapies. Click to learn more: boston.cbslocal.com/2021/04/14/age…
Agenus subsidiary @Agentus_CellTX dosed the first cancer patient with its iNKT #celltherapy! Watch Dr. @JoeGrossman7 discuss this immunotherapy and its potential to treat both #cancer and #COVID19.
Agenus Doses First Cancer Patient with iNKT Cell Therapy investor.agenusbio.com/news-releases/… The Phase 1 trial has been initiated in hematologic cancers @DanaFarber with expansion into solid tumors expected to begin shortly. Initial data readouts anticipated in 4Q2021 @Agentus_CellTX
Agenus' next-generation anti-CTLA-4 AGEN1181 is optimally designed with differentiated activity seen in the clinic. Watch $AGEN's CMO @ODayMD discuss the power of this cancer immunotherapy & the exciting responses presented at #AACR21! Click to learn more: investor.agenusbio.com/news-releases/…
New Clinical Responses for AGEN1181 Presented at #AACR21 investor.agenusbio.com/news-releases/…
Dr. @jbuell01, President & COO of $AGEN, will participate in the Precision Medicine in IO Panel at the 7th Annual Digital Immuno-Oncology Innovation Forum #sachs_IOIF #immunooncology #immunotherapy #precisionmedicine twitter.com/SachsAssociate…
Dr. Buell(@jbuell01) brings over 20 years of biopharmaceutical industry experience. Her efforts in the rapid advancement of discovery candidates through development has resulted in @Agenus_Bio' record of advancing numerous I-O candidates to the clinic in the past four years. pic.twitter.com/yObbEUhqPw
— Sachs Associates (@SachsAssociates) April 7, 2021
$AGEN senior management take bonus in equity over cash: investor.agenusbio.com/node/17711/html investor.agenusbio.com/node/17721/html
$AGEN latest newsletter now available: Optimally Targeting TIGIT TIGIT has emerged as the next validated I-O target w the potential to be a game-changing therapy for cancer patients. Click to read about the science of TIGIT & our bispecific AGEN1777: agenusbio.com/newsletters/v4…
Please to participate in #longwoodhealthcareleaders conference to discuss @Agenusbio #AI efforts & describe our #VISION Immune Platform to predict patient response twitter.com/LongwoodFund/s… Retweeted by Agenus Inc. ($AGEN)
Agenus @ #SGOMtg! @omalleygynonc presents on our RaPiDS trial, a collaboration w @GOG expected to further validate the use of bal+/-zal in 2L #cervicalcancer. Watch Dr. O'Malley discuss the trial & the potential to provide treatment to even more #patients agenusbio.com/newsletters/v4…
$AGEN latest newsletter now available: The Central Role of iNKT Cells: An Agenus Perspective This newsletter highlights the central role of iNKT cells in the immune system & their diverse functionality. Click to read more: agenusbio.com/newsletters/v4…
$AGEN Corporate Update and Fourth Quarter & Full Year 2020 Financial Report investor.agenusbio.com/news-releases/…
$AGEN will present @AACR #AACR21 on next-gen #CTLA4 AGEN1181 which shows increased efficacy & improved safety profile over first-generation anti-CTLA-4. Stay tuned for Exploring AGEN1181, a series of posts discussing its optimized design & promising data! investor.agenusbio.com/news-releases/…
Agenus to Present New Clinical Data on AGEN1181 at AACR 2021 investor.agenusbio.com/news-releases/…
$AGEN latest newsletter now available: Novel Immune Tools Tutorial: TIGIT, iNKTs, CTLA-4 In this newsletter, we give deeper insights into the science behind some of our exciting emerging medicines: CTLA-4, TIGIT, & iNKT cells. Click to read more: agenusbio.com/v4-i05_2021-no…
$AGEN & @Agentus_CellTX CTO Dr. Marc van Dijk spoke @CAR_TCell #CARTEU about the potential of iNKT #celltherapy, clinical plans in #cancer & #Covid_19, & combination potential w Agenus' checkpoint antibodies. Watch the replay for more insights: investor.agenusbio.com/events/event-d…
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2020 Financial Report investor.agenusbio.com/news-releases/…
$AGEN latest newsletter now available: Overcoming the Limitations of Current PD-1s Our PD-1 bal shows activity regardless of patients' #PDL1 status in R/M #cervicalcancer. Read about this potential differentiator & our work to identify better biomarkers: agenusbio.com/v4-i04_2021-ov…
S1E1 of Agenus Insights discussed #TIGIT the next validated #IO target in the immune revolution. @jbuell01 probed @ODayMD & @dhanschand on the key attributes of $AGEN TIGIT bispecific & what it adds to the current TIGIT landscape. See the replay for more: investor.agenusbio.com/events/event-d…
$AGEN CTO Dr. Marc van Dijk to speak at #CARTCR Summit Europe on Wed Feb 17 @ 11am GMT on "Providing Mechanistic Rationale for Combination Therapies Through Functional Characterisation." Click to learn more & to register: cartcr-europe.com @CAR_TCell @Agentus_CellTX